New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration July 14, 2022July 14, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New two-year data for Roche’s Vabysmo and Susvimo…New two-year data for Roche’s Vabysmo and Susvimo…The Lancet publishes studies showing Roche’s…The Lancet publishes studies showing Roche’s…New phase III data show Roche’s Vabysmo rapidly…Positive topline phase III results show Roche's…
